Magnitude and dynamics of the T-cell response to SARS-CoV-2 infection at both individual and population levels
Thomas M. Snyder(Adaptive Biotechnologies (United States)), Jason D. Goldman(University of Washington), Clifton L. Dalgard(Uniformed Services University of the Health Sciences), Summer Elasady(Institute for Systems Biology), Camillo Rossi(Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia), Camille Alba(Henry M. Jackson Foundation), Massimiliano Mazza(University of Milan), Lance Baldo(Adaptive Biotechnologies (United States)), Damon May(Adaptive Biotechnologies (United States)), Laura Rachele Bettini(Azienda Ospedaliera San Gerardo), Santiago Barrio, Edward J. Osborne(Adaptive Biotechnologies (United States)), Gladys J. Keitany(Adaptive Biotechnologies (United States)), Ottavia M. Delmonte(National Institutes of Health), Hope O’Donnell(Adaptive Biotechnologies (United States)), Eugenia Quirós-Roldán(Karolinska Institutet), Kerry Dobbs(National Institute of Allergy and Infectious Diseases), Fabio Nicolini(Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori), Vittorio Sambri(Azienda Unità Sanitaria Locale Della Romagna), Simona Semprini(University of Bologna), Hussein Al-Asadi(University of Chicago), Andrea Biondi(University of Milano-Bicocca), Ravi Pandya(Microsoft (United States)), Patrícia de Almeida, Peter Ebert(Heinrich Heine University Düsseldorf), Luisa Imberti(Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia), Ruth Taniguchi(Adaptive Biotechnologies (United States)), Rocío Laguna‐Goya(Research Institute Hospital 12 de Octubre), Mariella D’Angiò(University of Milano-Bicocca), H. Jabran Zahid(Microsoft (United States)), Quinn DeGottardi(Adaptive Biotechnologies (United States)), Rachel M. Gittelman(Adaptive Biotechnologies (United States)), Emily Svejnoha(Adaptive Biotechnologies (United States)), Claudio Cerchione(Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori), Giovanni Martinelli(University of Bologna), Julia Greissl(Microsoft (United States)), Gonzalo Carreño‐Tarragona, Mitchell W. Pesesky(Adaptive Biotechnologies (United States)), Paolo Bonfanti(University of California San Diego), Mark R. Klinger(Adaptive Biotechnologies (United States)), Jennifer N. Dines(Adaptive Biotechnologies (United States)), Miranda F. Tompkins(Uniformed Services University of the Health Sciences), Allen M. Vong(Adaptive Biotechnologies (United States)), Rebecca Elyanow(Adaptive Biotechnologies (United States)), Xiaoyu Chen(Tianjin Medical University), Alessandra Sottini(Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia), Matthew T. Noakes(Adaptive Biotechnologies (United States)), Ian M. Kaplan(Adaptive Biotechnologies (United States)), Jennifer Lu(Adaptive Biotechnologies (United States)), Paul Fields(Adaptive Biotechnologies (United States))
Cited by 11
Related Papers
Revised Recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia
|Journal of Clinical Oncology|2003|2.7k
Gilteritinib or Chemotherapy for Relapsed or Refractory <i>FLT3</i> -Mutated AML
|New England Journal of Medicine|2019|1.3k
International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts
|Blood|2015|1.2k
Early T-cell precursor leukaemia: a subtype of very high-risk acute lymphoblastic leukaemia
|The Lancet Oncology|2009|1k